Winfield Associates Inc. purchased a new position in Portola Pharmaceuticals Inc (NASDAQ:PTLA) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,445 shares of the biopharmaceutical company’s stock, valued at approximately $307,000.
Several other large investors also recently modified their holdings of the stock. Advisor Group Inc. increased its stake in shares of Portola Pharmaceuticals by 7.9% in the second quarter. Advisor Group Inc. now owns 9,302 shares of the biopharmaceutical company’s stock worth $252,000 after buying an additional 681 shares during the last quarter. Empire Life Investments Inc. increased its stake in shares of Portola Pharmaceuticals by 1.6% in the second quarter. Empire Life Investments Inc. now owns 59,159 shares of the biopharmaceutical company’s stock worth $1,604,000 after buying an additional 940 shares during the last quarter. Valley National Advisers Inc. increased its stake in shares of Portola Pharmaceuticals by 32.0% in the second quarter. Valley National Advisers Inc. now owns 4,046 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 981 shares during the last quarter. Next Capital Management LLC bought a new stake in shares of Portola Pharmaceuticals in the second quarter worth $27,000. Finally, United Services Automobile Association boosted its holdings in Portola Pharmaceuticals by 0.9% in the second quarter. United Services Automobile Association now owns 124,554 shares of the biopharmaceutical company’s stock worth $3,379,000 after purchasing an additional 1,065 shares during the period.
In other news, Director Hollings Renton sold 5,000 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now owns 18,194 shares of the company’s stock, valued at $545,820. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.50% of the company’s stock.
A number of research firms have commented on PTLA. Morgan Stanley began coverage on shares of Portola Pharmaceuticals in a report on Thursday, September 5th. They issued a “hold” rating and a $37.00 price objective for the company. Citigroup decreased their price objective on shares of Portola Pharmaceuticals from $51.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, October 9th. BidaskClub downgraded shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, September 26th. Cowen reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Portola Pharmaceuticals in a report on Thursday, August 8th. Finally, ValuEngine downgraded shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $39.29.
Portola Pharmaceuticals stock traded up $0.58 during mid-day trading on Thursday, reaching $28.02. The company’s stock had a trading volume of 30,749 shares, compared to its average volume of 795,142. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -5.62 and a beta of 2.09. The business has a 50 day moving average price of $28.33 and a 200-day moving average price of $29.49. The company has a current ratio of 3.63, a quick ratio of 3.61 and a debt-to-equity ratio of 453.47. Portola Pharmaceuticals Inc has a twelve month low of $14.81 and a twelve month high of $37.95.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. The firm had revenue of $28.42 million during the quarter, compared to the consensus estimate of $25.42 million. Portola Pharmaceuticals had a negative net margin of 379.94% and a negative return on equity of 352.12%. The firm’s revenue was up 608.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.61) earnings per share. On average, equities analysts expect that Portola Pharmaceuticals Inc will post -3.75 EPS for the current fiscal year.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Further Reading: What is a Call Option?
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.